Cargando…
P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430497/ http://dx.doi.org/10.1097/01.HS9.0000847188.87255.f7 |
| _version_ | 1784779785463922688 |
|---|---|
| author | Fedorova, L. Lepik, K. Mikhailova, N. Kondakova, E. Komarova, Y. Popova, M. Kotselyabina, P. Borzenkova, E. Baykov, V. Moiseev, I. Kulagin, A. |
| author_facet | Fedorova, L. Lepik, K. Mikhailova, N. Kondakova, E. Komarova, Y. Popova, M. Kotselyabina, P. Borzenkova, E. Baykov, V. Moiseev, I. Kulagin, A. |
| author_sort | Fedorova, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430497 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94304972022-08-31 P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA Fedorova, L. Lepik, K. Mikhailova, N. Kondakova, E. Komarova, Y. Popova, M. Kotselyabina, P. Borzenkova, E. Baykov, V. Moiseev, I. Kulagin, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430497/ http://dx.doi.org/10.1097/01.HS9.0000847188.87255.f7 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Fedorova, L. Lepik, K. Mikhailova, N. Kondakova, E. Komarova, Y. Popova, M. Kotselyabina, P. Borzenkova, E. Baykov, V. Moiseev, I. Kulagin, A. P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title | P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title_full | P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title_fullStr | P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title_full_unstemmed | P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title_short | P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA |
| title_sort | p1080: comparison of nivolumab 40 mg efficacy versus 3 mg/kg in patients with relapsed and refractory classic hodgkin lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430497/ http://dx.doi.org/10.1097/01.HS9.0000847188.87255.f7 |
| work_keys_str_mv | AT fedoroval p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT lepikk p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT mikhailovan p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kondakovae p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT komarovay p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT popovam p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kotselyabinap p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT borzenkovae p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT baykovv p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT moiseevi p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma AT kulagina p1080comparisonofnivolumab40mgefficacyversus3mgkginpatientswithrelapsedandrefractoryclassichodgkinlymphoma |